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SUMMARY
[3H]Dihydroalprenolol ([3H]DHA) has been used extensively in
receptor binding studies to measure $-adrenergic receptors in
the central nervous system. Usually, nonspecific binding has
been defined by high concentrations of the fl-adrenergic receptor
agonist isoproterenol or antagonists such as alprenolol or pro-
pranolol. Scatchard plots of such “specific” [3H]DHA saturation
data in rat cerebral cortex membranes are linear. However,
computer analysis demonstrated that the competition curves of
these drugs for 2.0 n [3H]DHA binding are biphasic, with a
continuous inhibition of [3HJDHA binding in the concentration
range usually used to determine nonspecific binding. These data
indicate that another saturable high affinity site was being labeled
by the radioligand and that the definition of nonspecific binding
with any of these unlabeled drugs is not satisfactory. We used
the nonlinear, least squares, curve-fitting program LIGAND to
analyze total [3H]DHA binding, allowing the program to mathe-
matically define nonspecific binding as a function of 3H-Iigand
concentration. Significantly lower Bmax (44%) and Kd (-58%)
values for f3-adrenergic receptors were found, indicating that
under normal experimental procedures (defining [3H]DHA non-
specific binding with these nonradioactive drugs) a second bind-
ing site was being labeled. We found that [3HJDHA binding to
this site could be inhibited by drugs such as RU24969, a 5-
hydroxytryptaminelA (5HT1A) and 5HT1B receptor subtype-selec-
tive agonist, and CGS1 2066B, a 5HT1B receptor subtype-selec-
tive agonist, which were able to compete for 1 5-20% of [3H]
DHA binding in the nanomolar concentration range, whereas
drugs that are selective for other serotonin receptor subtypes
inhibited [3H]DHA binding only at much higher concentrations.
Another 3-adrenergic receptor antagonist radioligand, [3H]CGP-
1 21 77, was found to be more selective for f3-adrenergic recep-
tors. Aiprenolol competition curves for [3H]CGP-1 21 77 binding
were monophasic and saturation curves, with nonspecific binding
defined either by 10 M alprenolol or by LIGAND, yielded Bmax
values close to those obtained with [3HJDHA when its nonspecific
binding was defined by LIGAND. [3HJDHA cannot be considered
a suitable radioligand to quantify central nervous system 3-
adrenergic receptors in the manner in which it has been typically
used.
[H]DHA was one of the first radioligands used to identify
peripheral fl-adrenergic receptors (1, 2). This ligand was then
used to identify f3-adrenergic receptor sites in the mammalian
CNS (3) and has been used in many studies since, especially
those investigating the regulation of 3-adrenergic receptors by
pharmacological treatments with antidepressant drugs (4, 5).
Although it is known that the proportions of fl and 132 subtypes
of adrenergic receptors vary between brain regions (6, 7), most
studies do not differentiate between the subtypes and consider
that [‘HIDHA labels both subtypes with equal affinity. In fact,
it is known that [1H]DHA has a slightly higher affinity for $-
versus  -adrenergic receptors (8).
This research was supported by Public Health Service Grants DA 04612 and
a Research Scientist Development Award MH 00316 to IC. and a postdoctoral
fellowship from Rutgers, the State University of New Jersey, to MR.
Stone and U’Prichard (9) suggested that [3H]DHA may also
label other sites besides fl-adrenergic receptors in the rat brain-
stem, although they did not characterize them or investigate
other brain regions. The possibility that other sites are also
labeled in the cortex is reinforced by the independent obser-
vations of Sulser and Kellar and their co-workers (10, 11), who
have found that alterations in f!-adrenergic receptor-linked
adenylate cyclase activity do not necessarily parallel changes
in -adrenergic receptors measured with [tHJDHA and that
manipulations of serotonergic systems can alter the binding
characteristics of this ligand. Recently, other fl-adrenergic li-
gands, which were introduced and characterized after [H]
DHA, have been shown to label serotonin receptors (12, 13).
The specificity of the receptor binding of a radioligand is
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dependent upon two characteristics, 1) the differential affinities
of the radioligand for its various binding sites and 2) the
selectivity and affinities of competing nonradioactive drugs that
are used to saturate specific receptor sites and, hence, define
“nonspecific” or nonreceptor binding of the radioligand. In the
case of [H]DHA, micromolar or higher concentrations of the
fl-adrenergic receptor antagonists alprenolol or propranolol
have generally been used to define its nonspecific binding.
However, these drugs have been shown, in studies with other
radioligands, to have some affinity for serotonergic receptor
sites (14, 15).
Recently, it has become possible to analyze the receptor
binding of a radioligand directly, without the use of a high
concentration of a nonradioactive drug to define nonspecific
binding. This method of analysis makes use of the iterative,
nonlinear regression, curve-fitting program LIGAND, which
fits saturation binding data, according to the law of mass action,
for the binding of the radioligand to one or more saturable
(putative receptor) sites plus nonspecific binding, which is
fitted as a linear function of radioligand concentration (16).
This method provides major advantages over the typically used
Scatchard analysis (17, 18). In competition studies, where in-
creasing concentrations of a nonradioactive drug compete for
the binding sites occupied by a fixed concentration of radioli-
gand, the program LIGAND can also be used to analyze the
binding of both the radioactive and nonradioactive ligands to
single or multiple sites, with nonspecific binding either defined
experimentally (by a high concentration of any nonradioactive
drug) or fitted by the program to the competition curve under
analysis.
In this paper, we have reevaluated the binding of [H]DHA
to CNS receptor sites, defining “nonspecific” binding by LI-
GAND or by use of drugs that have been commonly used in
other investigations, and we compared the results with those
of a novel (3-adrenergic receptor radioligand, [H]CGP-12177
(19). Our conclusion is that [:H]DHA is not suitable for meas-
uring f3-adrenergic receptors as it has been used typically and
the other site(s) that it labels cannot be easily characterized.
Materials and Methods
Animals and tissue preparation. Adult male Sprague Dawley rats
(Charles River, Wilmington, MA), weighing 200-300 g, were used
throughout the experiments; they were housed in group cages under
standard conditions (12-hr light-dark cycle) with free access to food
and water. The animals were killed by decapitation (between 10 a.m.
and 1 p.m.) and the brains were immediately removed into ice-cold
saline. Brain regions were rapidly dissected, placed into plastic vials,
frozen on dry ice, and stored at -70’ until the day of the experiment.
Rat cerebral cortices were homogenized in 50 volumes of cold 50 mM
Tris.HC1 (pH 7.7 at 25’) and centrifuged three times at 35,000 x g for
20 mm.
$-Adrenergic receptor binding. Two different ligands were used
to measure (-adrenergic receptor binding to rat cerebral cortex mem-
branes, [H]DHA (specific activity, 52.3-95 Ci/mmol; New England
Nuclear, Boston, MA) and [H]CGP-12177 (specific activity, 53 Ci!
mmol; Amersham Corporation, Arlington Heights, IL). Binding was
performed in borosilicate disposable tubes. The final assay volume of
2 ml consisted of 100 tl of radiolabeled ligand, 100 il of 10 sM
alprenolol, propranolol, or isoproterenol to measure the “nonspecific”
binding, competing drug as required, or incubation buffer (50 mM Tris.
HC1, pH 7.7 at 25’), 800 MI of incubation buffer, and 1 ml of membrane
suspension (6 mg of wet weight tissue/tube) added at the start of the
incubation.
The test tubes were incubated for 30 mm at 37 , then filtered under
vacuum through Whatman GF/C filters, and washed three times with
5 ml of ice-cold Tris buffer, using a modified Brandel cell harvester.
Filters were placed in plastic mini-scintillation vials and 5 ml of
Ecolume (ICN Biomedicals, Inc.) were added. Radioactivity trapped on
the filters was counted using a Beckman LS 5000 TD scintillation
counter at an efficiency of 43%.
In saturation experiments, [H]DHA was usually incubated in a
concentration range of 0.2 to 6.0 nM, whereas 2.0 nM [H]DHA was
used in competition experiments unless stated otherwise. In a typical
experiment, at K concentration the total and nonspecific (defined by
10 zM alprenolol) binding for [tHJDHA were 2183 and 471 cpm.
Saturation curves of lHICGP-12177 were performed in a concentra-
tion range of 0.025 to 2.0 nM, whereas in competition studies 0.2 nM
[H]CGP-12177 was used. In a typical experiment, at K,1 concentration
the total and nonspecific (defined by 10 MM alprenolol) binding for
[H]CGP-12177 were 679 and 51 cpm.
Data analysis. The weighted, nonlinear least squares, curve-fitting
program LIGAND was used for the analysis of saturation and compe-
tition experiments (16). Saturation experiments were analyzed either
by fitting the specific binding (defined as the difference between total
binding and nonspecific binding, which was delineated by the compet-
ing nonradioactive drug) or by fitting the total binding with the
nonspecific binding allowed to float and being fitted by the program as
a linear function of H-ligand concentration. All saturation and com-
petition studies were initially analyzed with a one-site model (i.e., one
saturable binding site); the data were then analyzed according to a two-
site model (i.e., two distinct saturable binding sites of different affini-
ties) and the results of this curve fitting were statistically compared
with a one-site model by an F test. The two-site model was accepted if
the fit was significantly better (p < 0.05) with respect to the one-site
analysis. Nonspecific binding in the competition experiments either
was fixed to the value defined by 10 sM alprenolol or was determined
by LIGAND from curve fitting of the competition of the nonradioactive
drug under examination. LIGAND also allows for the simultaneous
analysis of multiple competition curves for the same ligands, providing
more information for the accurate calculation of binding parameters.
When comparisons between assays with different definitions of
nonspecific binding were made, an ANOVA test was used and a direct
comparison between any two groups was made by Dunnett t test. When
comparisons were made between assays run in parallel on the same
tissue samples, comparisons were also made by paired Student’s t test.
Drugs. The following drugs were donated: CGP-12177 (Ciba Geigy),
RU24969 (Dr. S. Peroutka, Stanford University or Roussel), metergo-
line (Dr. L. Meyersen, Lederle), mesulergine (Dr. S. Peroutka, Stanford
University or Sandoz), ketanserin tartrate and spiperone (Janssen
Pharmaceutica), quipazine maleate (Dr. S. Peroutka, Stanford Univer-
sity), and IC! 89,406 (Imperial Chemical Industries).
The following compounds were purchased: [H]DHA (NEN Dupont),
(_)E:H]CGp42177 (Amersham), l-alprenolol d-tartrate, l-(-)-isopro-
terenol d-bitartrate, GTP Tris salt and DL-propranolol hydrochloride
(Sigma), and 8-OH-DPAT and CGS-12066B (Research Biochemicals
Incorporated).
Results
Characterization of [H]DHA binding. Aiprenolol and
propranolol have been used in many studies to define nonspe-
cific binding of [H]DHA to 3-adrenergic receptors. A concen-
tration of 1-10 M has been used typically. To ensure that only
a single homogeneous population of receptor binding sites is
being identified, the competition curve of these drugs should
have a pseudo-Hill slope of 1.0 and concentrations of the
competing drug higher than the concentration used to define
nonspecific binding should not inhibit the binding of the radi-
oligand further. Fig. 1 shows a typical competition curve of
alprenolol for [HIDHA binding. As can bee seen, competition
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Furthermore, it suggests that no concentration of alprenolol or
propranolol can satisfactorily be used to define [H]DHA spe-
cific binding to (3-adrenergic receptors.
In order to analyze these curves by LIGAND, it is first
necessary to determine the affinity of [HJDHA for the binding
sites that it is identifying. This is done by conducting saturation
experiments investigating the binding of increasing concentra-
tions of [H]DHA. If nonspecific binding was defined by 10 tM
alprenolol, Scatchard analysis of such “specific” [ HJDHA
binding indicated binding to a homogeneous population of sites
with a K(j of 1.48 ± 0.10 nM and a ,,,,,  of 9.86 ± 0.33 fmol/mg
of tissue (16 experiments) (Fig. 3A). Analysis of the same data
(nonspecific binding defined by 10 pM alprenolol) with LI-
GAND yielded a best fit to a single-site model, with a K,, of
1.42 ± 0.10 nM and a B ,,,,,  of 9.61 ± 0.33 fmol/mg of tissue (16
experiments) (see Table 1). LIGAND and Scatchard analysis
of [H]DHA saturation curves, with nonspecific binding defined
by 10 MM propranolol, yielded similar although significantly
higher values, with a K,1 of 2.31 ± 0.26 nM and a B,,.,. of 11.67
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log [ALPRENOLOL] (M)
Fig. 1. Typical competition curve of aiprenolol for [3H]DHA binding in rat
cerebral cortex membranes. The concentration of [3H]DHA was 2.0 n.
Nonspecific binding was defined by the curve-fitting program LIGAND
and it was determined to be 18% of total[3H]DHA binding. The alprenolol
competition curve fit best to a two-site model (p < 0.001), with K5 =
1 .65 ± 0.18 nM and K,. = 7.37 ± 2.35 zM (mean ± SE of 12 separate
competition expenments)when the affinity of[3H]DHA for the high affinity
fl-adrenergic receptor site was fixed at 0.6 n and its affinity for its
second binding site was defined by LIGAND. The affinity of [3HJDHA
determined for the second site was 6.64 ± 0.71 n (see text for
explanation). The densities obtained for the two sites were RH = 6.26 ±
0.25 fmol/mg of tissue and RL = 6.47 ± 0.53 fmol/mg of tissue.
-12 -10  -8  -6 
log [PROPRANOLOL] (M)
Fig. 2. Typical competition curve of propranolol for [3H]DHA binding in
rat cerebral cortex membranes. The concentration of [3H]DHA was 2.0
nM. Nonspecific binding was defined by LIGAND and it was determined
to be 22% of total [3H]DHA binding. The curve was best fit to a two-site
model (p < 0.001), with KH = 2.94 ± 0.51 n and KL = 2.31 ± 0.91 #M.
These values were obtained setting the affinity of [3H]DHA for the two
sites at 0.6 n. When the affinity of [3H]DHA for the second site was set
at 6.64 n, as obtained from [3H]DHA/alprenolol competition curves, the
determined affinities of propranolol for the two sites were KH = 2.91 ±
0.53 n and K,. 7.79 ± 3.18 M, whereas the capacities of the two
sites were RH 5.36 ± 0.32 and RL 6.95 ± 0.28 fmol/mg of tissue.
of alprenolol for [tH]DHA binding is steep between 0.1 and
100 nM, at which point the curve tends to level off but continues
to decrease gradually to the highest concentration studied, 100
tM. Fig. 2 shows a typical competition curve of propranolol for
[:tH]DHA binding; also with this drug a continuous inhibition
of the binding occurs in the concentration range currently used
to define the nonspecific binding of [H]DHA. The shape of
these curves suggests that more than one site is being labeled.
Fig. 3. Scatchard plots of typical [3HJDHA saturation experiments in rat
cerebral cortex membranes with nonspecific binding defined by 10 M
aiprenolol. The lines were calculated by linear least-squares analysis. A,
[3H]DHA was used in a concentration range of 0.2 to 5.0 n. The
Scatchard plot for a single site (correlation coefficient, r = 0.97) yielded
a !( of 1 .41 nM and a Bma. of9.88 fmol/mg of tissue. B, The concentration
range of [3H]DHA was between 0.2 and 16 n. The Scatchard plot for a
single site (correlation coefficient, r = 0.89) yielded a Kd of 1 .94 n and
a B, of 13.08 fmol/mg of tissue.
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TABLE 1
Nonlinear regression analysis (LIGAND) of saturation data for [3H]DHA and [3HJCGP-12177 binding to $-adrenergic receptors in rat
cerebral cortex membranes
Saturatton expenments were performed as described in Materials and Methods and were analyzed by the computer program LIGAND. All data were best fit to a single
saturable site; the values in the table are the means ± standard error of n separate determinations.
3H-Ligand n on:: cd B, K5
fmo!/mg of tissue flM
[‘H]DHA 16 10 M Alprenolol 9.61 ± 0.33 1 .42 ± 0.10
[3HJDHA 4 10 MM Isoproterenol 6.04 ± 0.228 0.95 ± 0.21
[‘H]DHA 7 10 zM Propranolol 1 1 .67 ± 0.66k’ 2.31 ± 0.26k’
E3HIDHA 16 LIGAND program 5.42 ± 0.19 0.60 ± 0.05’
[‘H]CGP-12177 12 10 M Alprenolol 4.99 ± 0.12a 0.13 ± 0.01
[‘H)CGP-12177 12 LIGAND program 4.46 ± 0.18a 0.10 ± 0.01
. P < 0.001 versus I3HIDHA binding in which the nonspecific binding was determined by 1 0 gM aiprenolol or 10 MM propranolol (Dunnett t test).
5 ,, < 0.01 versus (3HJDHA binding in which the nonspecific binding was determined by 1 0 gM alprenolol (Dunnett t test).
 p < 0.001 versus I3HJDHA binding in which the nonspecific binding was determined by 10 MM alprenolol (paired t test on 16 pairs run in parallel).
dp < 0.05 versus I3HIDHA binding in which the nonspecific binding was determined by 10 MM alprenolol (paired t test on 16 pairs run in parallel).
#{149}p< 0.01 versus [3HJDHA binding in which nonspecific binding was determined either by 10 pM isoproterenol or by LIGAND program (Dunnett t test).
, p < 0.05 versus I3HICGP-1 21 77 binding in which the nonspecific binding was determined by 1 0 MM alprenolol (paired t test on 1 2 pairs run in parallel).
± 0.66 fmol/mg of tissue. However, if nonspecific binding was
not defined by a competing nonradioactive drug and the pro-
gram LIGAND was allowed to fit the total binding of [H]DHA
to one or more saturable sites with nonspecific binding as a
linear function of [HIDHA concentration, only a single satu-
rable binding site could be identified, with a K,1 of 0.60 ± 0.05
nM (p < 0.05 versus [H]DHA binding with nonspecific binding
defined by 10 zM alprenolol) and a significantly lower B,, of
5.42 ± 0.19 fmol/mg of tissue (p < 0.001) (see Table 1).
We used the K,, determined from the saturation data by
LIGAND (with nonspecific binding determined by the pro-
gram) to reanalyze the competition curves of alprenolol and
propranolol for [ HJDHA binding that are shown in Fig. 1 and
2. With both drugs, a two-site fit was significantly better than
a one-site fit (p < 0.001), with values for the affinities of
alprenolol being K,, = 1.65 ± 0d8 nM and K1. = 2.52 ± 0.81 sM,
with 78 ± 2% representing the high affinity sites; the parame-
ters for propranolol were K,, = 2.94 ± 0.51 nM, K1. = 2.31 ±
0.91 tM, and 72 ± 1% was represented by the high affinity site.
For this analysis, the affinity of [H]DHA for binding to the
second site was fixed to be the same as the affinity determined
by LIGAND for the first site (presumptive f3-adrenergic recep-
tors), because Scatchard or LIGAND analysis had resolved
only a single homogeneous population of [H]DHA binding
sites.
It was obvious, however, from the analysis of the saturation
data comparing the results using nonspecific binding either
defined by 10 iM alprenolol or being calculated by LIGAND
that the affinity of [ H]DHA for the second site must be lower
than its affinity for the -adrenergic receptor sites because 1)
the K,, for the single highest affinity site (presumptive f3-
adrenergic receptors) determined by LIGAND analysis of total
binding was significantly lower than the K,, determined by
LIGAND or Scatchard analysis when nonspecific binding was
determined by 10 MM alprenolol, which would have included
binding to the second site in the analysis; and 2) when increas-
ing concentrations of [H]DHA were included in the experi-
ment in an attempt to determine the characteristics of the
second site, the Scatchard plots became curvilinear and showed
continual increases in K,, and B,,. when the data were analyzed
as binding to a single site (Fig. 3B). However, it was impossible
for LIGAND to resolve specific binding, either defined by 10
M alprenolol or from total binding, into two saturable sites
(plus nonspecific binding). In all cases, only a single saturable
site could be defined. For example, if concentrations of up to
20 nM [H]DHA were included, LIGAND still analyzed the
total binding data as a single saturable binding site with the
same B ,,,  and K,, as were determined with saturation curves
when the highest concentration of [‘H]DHA was 6 nM. Thus,
the second site appeared not to saturate under the conditions
of the assay and LIGAND considered that the binding to it was
linear with increasing radioligand concentration and included
it in the determination of nonspecific binding. Whether or not
the second site, in reality, is not saturable is uncertain because,
at these high concentrations of [3H]DHA nonspecific binding
was so great that if the B ,,.  of the second site is not large (in
the same order as that of other neurotransmitter receptors,
about 10 fmol/mg of wet weight tissue) the noise in the data
would obviate its accurate determination by LIGAND.
Given that it appeared that the affinity of [H]DHA for the
second site was lower than that for f1-adrenergic receptors, we
reanalyzed the [:)HIDHA/alprenolol competition curves, letting
LIGAND determine the affinities of alprenolol for both the fi-
adrenergic receptor and the second site, while fixing only the
affinity of [H]DHA for the 3-adrenergic receptor population
as determined by LIGAND analysis of the saturation data. The
affinity of [H]DHA for the second site and its   values for
the two sites were allowed to float and be calculated by LI-
GAND. Under these conditions, LIGAND again determined
that a two-site fit for the competition curve for alprenolol was
significantly better than a single-site fit. However, this fit was
not significantly better from the two-site fit where the affinities
of [H]DHA for the (3-adrenergic receptor and the second site
were shared and set to the value determined for the fl-ad.renergic
receptor determined from the saturation studies. Although this
fit was not significantly better, the K,, that was determined may
give some approximation of the affinity of [H]DHA for the
second site. The average value that was determined (12 exper-
iments) for the affinity of [‘H]DHA for the second site was
6.64 ± 0.71 nM and the B ,,,,  for this site was 6.47 ± 0.53 fmol/
mg of tissue.
Isoproterenol, a f3-adrenergic receptor agonist, has also been
used in some studies to define nonspecific binding. However, a
problem with using agonists to define nonspecific binding is
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that in certain circumstances, especially if the receptor is
associated with a guanine nucleotide-binding protein, agonists
can demonstrate both high and low affinity binding compo-
nents. Thus, it can be unclear whether only the highest affinity
component defined by the agonist competition represents the
specific receptor binding or whether it is the two highest affinity
components that define the total population of receptors. In-
deed, as will be mentioned in the discussion, this had lead to a
good deal of confusion in the analysis of some experiments.
When we defined nonspecific binding by 10 tM isoproterenol
and conducted a saturation of [‘H]DHA binding, we obtained
a B,5,, that was close to the value determined by LIGAND
analysis of total binding with nonspecific binding calculated as
a linear function of :Hligand concentration (see Table 1),
suggesting that f.-adrenergic receptors, under these conditions,
demonstrate only a single affinity binding state. Competition
curves of isoproterenol for [‘HJDHA binding (Fig. 3) were best
fit by a two-site model, with the highest affinity component
having a K of 50.0 ± 3.7 nM and a Bm,x of 4.56 ± 0.32 fmol/mg
oftissue, similar to the Bma. of fl-adrenergic receptors as defined
by saturation experiments. The second site had a much lower
affinity (greater than 1 tM) and its Bn,ax approximated the B,5.
for the second site as defined by alprenolol competition curves.
In order to conduct this analysis, LIGAND was used to analyze
the competition curve for two sites and the affinity of [‘H]
DHA for the second site was fixed to the same value as its
highest affinity site (fl-adrenergic receptors) or the affinity of
the second site was set to 6.64 nM, as had been determined
from the aiprenolol competition analysis by LIGAND (Fig. 4).
Isoproterenol binding at both of the sites labeled by [‘H]
DHA was sensitive to GTP. The curves were shifted to the
0
IC.)
Zj
0
I-
Fig. 4. Typical competition curve of isoproterenol on total [3H]DHA
binding in the presence (U) or absence (0) of 300 MM GTP. The curves
(nine experiments) were analyzed by LIGAND and nonspecific binding
was defined by the program. The concentration of [‘HIDHA was 2.0 n.
Specific binding was 70% of total in the absence of GTP and 57% in the
presence of GTP. The competition curves of isoproterenol on [‘H]DHA
binding in the absence of GTP were best fit to a two-site model (p <
0.01) with K,, 50.0 ± 3.7 n and KL 7.18 ± 1 .79 sM. The capacities
of the two sites (fmol/mg of tissue) were RH = 4.56 ± 0.32 and RL =
6.38 ± 0.72. These parameters were obtained by fixing the affinity of
[3H]DHA for the high affinity site at 0.6 ni while its affinity for the second
site was set at 6.64 nM (the value obtained from aiprenolol competition
curves). The competition curves in the presence of GTP were best fit to
a one-site model, with K, = 174.5 ± 10.0 n (p < 0.01 versus K,, of
isoproterenol in the absence of GTP) and a density of 5.26 ± 0.46 fmol/
mg of tissue.
right and best fit to a single-site model in the presence of 300
zM GTP. The affinity of isoproterenol for the high affinity
binding site was lowered by a factor of 3, whereas the second
component, for which in the absence of GTP isoproterenol had
an affinity of 9.18 ± 1.79 tM, was not apparent in the presence
of GTP. Isoproterenol at 10 tM competed for only 57% of total
[‘H]DHA binding in the presence of 300 MM GTP versus 70%
of total [‘H]DHA binding in the absence of GTP. The total
binding of [‘H]DHA was not affected by 300 zM GTP. Impor-
tantly, the Bmax for the highest affinity site for isoproterenol
(4.56 ± 0.32 fmol/mg of tissue) was not significantly altered by
300 M GTP (5.26 ± 0.46 fmol/mg of tissue).
Characterization of [3H]CGP-12177 binding. We then
characterized the binding of another (3-adrenergic antagonist
radioligand, [:3H]CGp.12177. When [H]CGP-12177 saturation
curves were conducted using 10 zM alprenolol to define non-
specific binding, LIGAND analysis yielded a B,,,,,. of 4.99 ±
0.12 fmol/mg of tissue. This value was not significantly differ-
ent from the B,,,5. for [:4H]DHA binding calculated by LIGAND
with nonspecific binding as defined by the computer program
(Table 1). If LIGAND was used to define nonspecific binding
for [‘H]CGP-12177, the B,5. was 11% lower than if 10 iM
alprenolol was used to define nonspecific binding and it was
calculated as 4.46 ± 0.18 fmol/mg of tissue (p < 0.05, compared
with the alprenolol-defined B ,,,,, ; Table 1). This value was close
to, although significantly lower (p < 0.01, 12 experiments)
than, the Bmax calculated for [H]DHA binding using LIGAND
to define nonspecific binding.
The competition of alprenolol for [‘H]CGP-12177 (Fig. 5)
indicates that [‘H]CGP-12177 is a more specific f3-adrenergic
receptor radioligand than is [‘H]DHA. The LIGAND analysis
of this competition data was best fit to a single site with high
affinity for alprenolol (K, = 1.80 ± 0.16 nM) and the competition
curve leveled off between 0.1 and 100 zM alprenolol. Thus,
alprenolol would appear to be a satisfactory drug to define the
nonspecific binding of [:H]CGp42177 to fi-adrenergic recep-
tors.
In contrast to the competition of isoproterenol for [H]DHA
binding, where two sites were apparent, isoproterenol compe-
tition for [H]CGP-12177 binding was best fit to a one-site
0
Oz
0
LL
or::
z’-
mo
10
ZI
-C.)
Fig. 5. Typical competition curve of alprenololfor [‘H]CGP-l 21 77 binding
in rat cerebral cortex membranes. Alprenolol competition curves for 0.2
nM [‘H]CGP-12177 were monophasic, with a K, = 1 .80 ± 0.16 nri and a
B. = 5.16 ± 0.14 fmol/mg of tissue (mean ± SE of five separate
competition experiments). Nonspecific binding was defined by LIGAND
and amounted to 8% of total binding.
 at D
ip Farm
acol Chem
ioterap Tossicol M
ed Bibl Farm
acol M
ed Sper on July 22, 2008 
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
0
z
0
z
LL
0<
ZI
I0
ow
0
0
00
(I)
LLm#{176}r::
z,-
10
ZI
206 Riva and Crease
model, with a K, of 132 ± 8 nM and a B,,. of 5.17 ± 0.09 fmol/
mg of tissue, which was not significantly different from the
B ,,,,, . of [H]CGP-12177 binding determined from the saturation
experiments with nonspecific binding defined by alprenolol
(Fig. 6). It is interesting to note that the affinity of isoproterenol
for this single high affinity site was significantly lower (p <
0.01) than the affinity of isoproterenol for its high affinity site
identified in [HIDHA binding experiments (132 versus 50 nM).
GTP at 300 uM shifted the isoproterenol curve to the right and
its K, was increased by a factor of 2. Total [H]CGP-12177
binding was not altered by GTP, nor was the percentage of
binding that was displaced by 100 MM isoproterenol (90.3 ±
0.7%).
Fig. 7 shows a typical competition curve of nonradioactive
CGP-12177 for [:H1DHA binding sites. LIGAND analysis of
these competition curves was best fit by a three-site model (p
< 0.01). The highest affinity component had a K, of0.13 ± 0.03
nM (not significantly different from the K,, of [:H]CGp42177
binding to f3-adrenergic receptors in saturations experiments).
The B ,,,,  of this site (4.56 ± 0.34 fmol/mg of tissue) was also
identical to the B,.,. obtained in saturation experiments with
[H]CGP-12177. The second component of the CGP-12177
competition for [H]DHA binding labeled a site with a K, of
9.41 ± 1.95 nM and a B,,,. of 1.64 ± 0.28 fmol/mg of tissue. A
third component of binding had a K, of 47.7 ± 26.3 tM, when
the affinity of [H]DHA for that site was set to the approximate
affinity (as determined above) for the unknown site (6.64 nM).
In this case, the B,,.,. calculated for the third site was very
variable, ranging from 1.95 to 5.86 fmol/mg of tissue (average,
3.82 ± 0.65 fmol/mg of tissue), because the highest concentra-
tion of CGP-12177 used (100 .sM) was only slightly higher than
the determined K,, for this site.
Characterization of the lower affinity [‘H]DHA bind-
ing site. Because studies by other authors had indicated that
there was a potential serotonergic modulation of the lowest
affinity site for [H]DHA binding defined by isoproterenol (20),
-11 -9 -7 -5
log [ISOPROTERENOL] (M)
Fig. 6. Competition curve of isoproterenol on [‘H]CGP-12177 binding in
rat cerebral cortex membranes: effect of GTP. The curves in the presence
(U) or in the absence (0) of 300 iM GTP were analyzed by LIGAND and
were best fit to a single-site model. In the absence of GTP, the K, of
isoproterenol for l’H}CGP-l 21 77 binding was 132 ± 8 nM and the
measured density was 5.1 7 ± 0.09 fmol/mg of tissue, whereas in the
presence of GTP the K, was 263 ± 28 nri (p < 0.01 versus isoproterenol
in the absence of GTP) and the density was 5.1 0 ± 0.1 7 fmol/mg of
tissue. Specific binding was 90% of total binding in the presence or
absence of GTP.
log [CGP 12177] (M)
Fig. 7. Typical competition curve of [3H]CGP-1 21 77 on [3H}DHA binding
in rat cerebral cortex membranes. The concentration of [‘H]DHA was
2.0 ni. The curves, analyzed by LIGAND, fit best to a three-site model
(p < 0.01), with nonspecific binding defined by the program. When the
affinities of [‘H]DHA for the two highest affinity sites were set at 0.6 ni
and its affinity for the third site was fixed at 6.64 n, the determined K,
values for [‘H]CGP-12177 were: K,, = 0.13 ± 0.03 nM, K,2 = 9.41 ± 1.95
nM, and K,3 = 47.7 ± 26.3 MM. Their respective densities were R1 = 4.56
± 0.34, R2 = 1 .64 ± 0.28, and R3 = 3.82 ± 0.65 fmol/mg of tissue.
we investigated a number of different serotonergic ligands of
differing serotonin receptor subtype specificity for their ability
to compete for [:H1DHA binding. The selective 5HT,A receptor
ligand agonist 8-OH-DPAT, the semiselective 5HT1A and 5HT2
antagonist spiperone, the selective 5HT2 receptor antagonist
ketanserin, and the 5HT,(’ receptor antagonist mesulergine
only competed for [‘H}DHA binding at concentrations greater
than 1 sM. The 5HT,H receptor-selective agonist CGS12O66B
(21) and the semiselective 5HT,A/5HTl, receptor agonist
RU24969 both competed for a portion of [‘H]DHA binding in
the low nanomolar range. About 20% of 2.0 nM [‘H]DHA
binding was displaced by 500 nM concentrations of these drugs
(see Fig. 8). LIGAND analysis of these curves was best fit by a
two-site model, with a high affinity component amounting to
around 15-20% of “specific” [‘H]DHA binding as defined by
10 M alprenolol. In order to better determine the characteris-
tics of this high affinity site for the serotonergic ligands in the
LIGAND analysis, we set the affinity of [‘H]DHA for this site
as 6.64 nM (as determined from the alprenolol competition
curves) and the affinity of [‘H]DHA for the fl-adrenergic recep-
tor as 0.6 nM. These data are shown in Table 2, along with the
competition analyses of other selective serotonergic agonist!
antagonists. The serotonergic drugs were also investigated for
their ability to inhibit [:H]CGp42177 binding. None of the
drugs that were active in a nanomolar range on [H]DHA
binding inhibited [:H]CGp42177 binding at concentrations
<100 nM.
As discussed above, CGP-12177 competed for three sites in
[H]DHA binding experiments. In an attempt to see whether
its lowest affinity site was the serotonergic site and whether it
could be characterized in saturation studies, we masked the
binding of [H]DHA to the two highest affinity sites competed
for by CGP-12177, conducting a [:H]DHA saturation experi-
ment in the presence of 100 nM CGP-12177, with nonspecific
binding defined by 1 M CGS12O66B. Scatchard and LIGAND
analyses both yielded a similar K,, of 34 nM and a  of 16
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Fig. 8. Competition of serotonergic ligands for specific [3H]DHA binding
in rat cerebral cortex membranes. The concentration of [3H]DHA was
2.0 nM. The data were analyzed by LIGAND, with nonspecific binding
defined by 10 MM alprenolol. The competition curves of 8-OH-DPAT (Li),
mesulergine (0), and ketanserin (#{149})fit best to a single site, with their
respective K, values being 20.8, 7.2, and 17.1 tM. RU24969 4 and
CGS-1 2066B (0) competition curves were best fit to two sites (p <
0.05). The K, values of RU24969 for the two sites were K,, = 29.4 ± 9.0
nM and KL 756 ± 92 n, whereas the K, values of CGS-1 2066B were
KH=38.4 ± 14.2nMandK,. =576± l8nM.
fmol/mg of tissue for [H]DHA binding to this site. However,
not much reliance can be placed on these values, because
specific binding was only 23% of total binding at the highest
concentration (20 nM) of [:4H]DHA examined.
Resolution of [3HJDHA and [3HJCGP-12177 binding
to - and $2-adrenergic receptors. It has previously been
demonstrated that [:H]DHA and [:H]CGp12177 bind to both
flu - and fl2-adrenergic receptors. The regional distributions of
13,-adrenergic and 32-adrenergic receptors are not homogeneous,
there being a greater proportion of f,-adrenergic receptors in
the cortex and fl-adrenergic receptors in the cerebellum. Thus,
the saturation curves conducted in the cortex will have binding
parameters for the radioligands closer to their affinities for f3,-
adrenergic receptors, whereas saturations conducted in the
cerebellum will provide parameters approximating the affinities
of the radioligands for f32-adrenergic receptors. Some nonla-
beled ligands are more selective for /3,- or f32-adrenergic recep-
tors than the classical 3-adrenergic receptor antagonists; thus
TABLE 2
ICI 89,406 has a greater than 100-fold higher affinity for (3,-
than fl-adrenergic receptors (22), whereas ICI 118,551 has a
more than 50-fold higher affinity for (32- than (3-adrenergic
receptors (23). ICI 89,406 competed for [‘H]DHA binding in
the cortex according to a three-site model; the highest affinity
site had a K, of 0.85 ± 0.18 nM and a receptor density of 3.46
± 0.34 fmol/mg of tissue and the second site had a K, of 111.7
± 33.5 nM and a B ,,,,, , of 1.71 ± 0.32 fmol/mg of tissue. When
the K,, of [‘H]DHA for the third site was set at 6.64 nM, the
B ,,,,,  calculated for ICI 89,406 at this site was 6.70 ± 0.03 fmol/
mg of tissue, similar to that obtained from alprenolol competi-
tion curves, and the affinity of ICI 89,406 for the third site was
23.4 ± 5.7  On [‘H]CGP-12177 binding, ICI 89,406 competed
for only two sites; the highest affinity site had a K, of 1.02 ±
0.13 nM and a ,,, , of 4.49 ± 0.21 fmol/mg of tissue and the
second site had a K, of 117.9 ± 17.5 nM and a B,,. of 0.92 ±
0.10 fmol/mg of tissue. In these analyses, the K, values of [‘H]
DHA or [H]CGP-12177 for (3,- and (32-adrenergic receptors
were set equal to each other. In saturation studies of [H]CGP-
12177 binding in cerebral cortex versus cerebellum, the K,, was
0.11 ± 0.003 nM in the cortex versus 0.162 ± 0.008 nM in the
cerebellum (p < 0.05). Conversely, saturations of [H]DHA
binding (with nonspecific binding defined by LIGAND) yielded
K,, values in the cortex of 0.60 ± 0.05 nM versus 0.32 ± 0.05 (p
< 0.05) in the cerebellum. These data indicate some subtype
selectivity for both :H4igand5 which probably explains the
nonequality of the densities of (3,- and fl2-adrenergic receptors
determined with the radioligands and ICI 89,406.
Discussion
[:H]DHA has been used to characterize CNS (3-adrenergic
receptors in numerous studies (24). Nonspecific binding of [H]
DHA has been defined utilizing high (1-100 zM) concentrations
of the (3-adrenergic antagonists propranolol or alprenolol or the
agonist isoproterenol. The accurate quantification of (3-adre-
nergic receptor characteristics is dependent on the selectivity
ofboth the radioligand, [H]DHA, and the unlabeled competing
drug used to define nonspecific binding. Although Scatchard
analysis of “specific” [‘H]DHA binding, as defined by these
drugs, yields linear plots suggestive of selective (3-adrenergic
receptor labeling by [‘HIDHA, the results of the present paper
clearly demonstrate that [‘H]DHA is not a selective ligand for
(3-adrenergic receptors. Our data suggest that both [H]DHA
Nonlinear regression analysis (LIGAND) of the competition curves of various serotonergic agonists and antagonists for [3H]DHA and [3H]
CGP-12177 binding in rat cerebral cortex membranes
The values in the table are the result of at least three competition curves analyzed by LIGAND. In computer analysis of the competition curves, the K5 of I3HIDHA for the
unknown site was set at 6.64 n (see Fig. 1) while the K,, for the 3-adrenergic receptor site was set at 0.60 n.i. ND indicates that only one site was detected in the
competition curve analysis.
I3HIDHA bOding i’HCGP-12177 binding
D 5HT i-adrenergicrug receptor speciticity Unknown site -adrenergic receptor rec ptor
K, K, K,
flM
8-OH-DPAT 1A ND 20,806 ± 7,000 >10,000
Spiperone 1A, 2 15,229 ± 4,380 557 ± 176
RU24969 1A,1B 29.4±9.0 756±92. 564±160
CGS-12066B lB 38.4 ± 14.2 576 ± 18 649 ± 205
Mesulergine 1 C ND 7,1 72 ± 2,597 >10,000
Metergoline 1, 2 48.32 ± 11.87 2,348 ± 148
Ketansenn 2 ND 17,071 ± 3,928 >10,000
Quipazine 3 ND 2,006 ± 507
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plot were still very high (r > 0.87). However, even under these nents. LIGAND analysis suggests, from the similarity in B,5.
and the drugs used to define its nonspecific binding all bind to
a second site. This can lead to an overestimation of f3-adrenergic
receptors of nearly 2-fold.
Visual inspection of the competition curves for alprenolol,
propranolol, or isoproterenol on [:H]DHA binding (using a
concentration of [H]DHA close to its apparent affinity for /3-
adrenergic receptors) all demonstrated that the competition
curves continued to decrease with no leveling off at the concen-
trations of these drugs typically used to define nonspecific
binding. This observation immediately demonstrates that these
drugs cannot be used to define nonspecific binding and, thus,
the parameters of [“H]DHA binding to /3-adrenergic receptors
will not be determined accurately by typical methods such as
Scatchard analysis.
One may argue that a lower concentration of aiprenolol or
propranolol would be “safe” and provide an accurate determi-
nation of (3-adrenergic receptors. However, this suggestion can
be criticized for two reasons. 1) If both radioligand and displac-
ing drug bind to two distinct sites, albeit with different affini-
ties, there will always be contamination of one site by the other,
unless the displacing drug has such marked differences in
affinities for the two sites that its competition curve shows a
clear plateau (of at least 1 log unit), allowing for selective
displacement of the radioligand from only one of its binding
sites. This criterion is not met by either alprenolol or propran-
olol. 2) In using nonselective drugs, a great risk is run when
the system is manipulated via, for example, pharmacological or
surgical methods. A change in the affinities ofeither radioligand
or displacing drug for one or both of their binding sites would
invalidate the choice of the particular concentration of drug
used to define specific receptor binding in the control tissue.
The nonlinear, iterative, curve-fitting program LIGAND (16)
has the advantage that it can analyze the total binding of a
radioligand according to the law of mass action, with no as-
sumptions being necessary as to the pharmacological charac-
teristics of the binding sites that are being labeled. Saturation
data of “total” binding can be analyzed by the program without
information as to what was pharmacologically defined as spe-
cific versus nonspecific binding, by fitting the data points to
the theoretical curves that would be generated by the binding
of the radioligand to one, two, or more saturable sites plus
nonspecific binding, which is linearly proportional to the con-
centration of the radioligand. Such an analysis demonstrated
that [‘H]DHA binds to a single saturable site with a B,,,. (5.42
± 0. 19 fmol/mg of tissue) that was significantly lower than that
obtained using Scatchard analysis of specific binding defined
by the commonly used competing ligands (Table 1). Indeed,
even LIGAND analysis of specific binding defined by these
drugs gave a similar erroneous result. Alprenolol-defined spe-
cific binding was fitted best to a single site (B,1,., = 9.61 ± 0.33
fmol/mg of tissue) and LIGAND could not fit the specific
binding data to two saturable sites over the concentration range
of [‘HJDHA typically used in such studies. Scatchard plots of
such data, however, gave a visual indication that the plots were
not linear and, if the concentrations of [‘H]DHA used were
increased, the plots became more curvilinear, with a linear fit
producing increasing B,,. values as the highest concentration
of [‘H]DHA used in the saturation experiments was increased.
It is of interest to note that, even though the Scatchard plots
were clearly curvilinear, the correlation coefficients for a linear
circumstances of high [‘H]DHA concentrations, LIGAND
could not fit specific binding to more than one site. It was
apparent that the Kd of [‘H]DHA for its second binding site
must be appreciably higher than the K,, for (3-adrenergic recep-
tors but, because these sites did not appear to saturate, LI-
GAND could not accurately quantify them. The binding to this
second site was included within nonspecific binding by the
analysis because, at these high concentrations of [‘H]DHA, the
component of binding to the second site was small relative to
the high levels of noisy nonspecific binding.
Although LIGAND could not characterize the parameters of
the second site directly from the [‘H]DHA saturation experi-
ments, it was clear from the aiprenolol competition curves for
[:H]DHA binding that appreciable binding of [‘HIDHA and
alprenolol was occurring to this second site. We used LIGAND
analysis of the alprenolol competition curves for [‘H]DHA
binding to estimate the binding parameters of this site. The Kd
of [“H]DHA for the second site was determined to be approxi-
mately 6.64 ± 0.71 nM. Its Bm,,. was about 6.47 ± 0.53 fmol/mg
of tissue, within the general range of typical CNS neurotrans-
mitter receptor sites.
These approximate parameters for the second site were useful
in further characterizing the pharmacological specificity of this
site. Because other studies have suggested that /3-ad.renergic
ligands often label serotonin receptors (12, 13) and [‘H]DHA
binding has been shown recently to be sensitive to serotonin
(20), we investigated the competition of selective serotonin
receptor subtype agonists and antagonists for [“H]DHA bind-
ing. Although the majority of such drugs (5HT,A, 5HT,,., 5HT9,
and 5HT: receptor subtype selective) only competed for [‘H]
DHA binding at high concentrations, two drugs, RU24969 and
CGS12O66B, demonstrated about 20% competition at nanom-
olar concentrations (Fig. 8). Using the affinity determined by
LIGAND from the alprenolol competition curves for the second
site to analyze these 5HT,H receptor-selective drug competition
curves, we determined K, values for these drugs at the second
site to be on the order of 10-50 nM, similar to their affinities
for 5HT,B receptor sites. Metergoline, a potent antagonist at
all serotonergic receptors, also showed a competition curve that
best fit a two-site model, with the K, for the highest affinity
site being 48 nM, close to its reported affinity for 5HT1
receptors (25). This again suggested that the second site labeled
by [H]DHA could be a serotonergic binding site. The K, values
of RU24969 at the 5HT,H receptor binding site that other
authors have reported are lower than those we found for the
second site labeled by [‘H]DHA (25, 26). This could be due to
differences in buffer compositions, because receptor/agonist
interaction could be influenced by the presence of ions such as
Mg . However, we cannot conclusively determine whether [‘H]
DHA is binding to 5HT,  receptors because the “binding sig-
nal” of [‘H]DHA at this unknown site is very poor, mitigating
against its accurate characterization.
Isoproterenol also suffered from problems similar to those of
alprenolol and propranolol when it was used to define specific
/3-adrenergic receptor binding. It also competed for [‘HJDHA
binding with two affinity components. Because isoproterenol is
an agonist, it is unclear whether the high and low affinity
binding sites represent high and low affinity conformations of
the (3-adrenergic receptor for the agonist or whether they rep-
resent two distinct binding sites on different cellular compo-
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values, that the high affinity site is indeed /3-adrenergic receptor
binding and that the lower affinity site is the non-/3-adrenergic
receptor site. This hypothesis is somewhat reinforced by the
finding that GTP causes a small shift in the affinity of isopro-
terenol for its highest affinity site (as might be expected for
the adenylate cyclase-linked /3-adrenergic receptor), whereas,
in contrast, it completely obliterated the low affinity competi-
tion of isoproterenol for [:IH]DHA binding. This suggests that
the second binding site for [:H]DHA is also associated with a
GTP-binding protein. If 10 aM isoproterenol was used to define
specific [:1H]DHA binding to /3-adrenergic receptors, a Bma. was
obtained by Scatchard and LIGAND analysis that was inter-
mediate between that defined by LIGAND analysis of total
binding or LIGAND analysis using specific binding defined by
alprenolol (Table 1). This suggests that studies that have used
isoproterenol at this concentration may more closely approxi-
mate true /3-adrenergic receptor characteristics. However, be-
cause the isoproterenol competition curve does not level off
and because agonist binding is typically sensitive to many
modulators such as the buffer ionic composition, pH, etc., as
well as guanine nucleotides, data obtained using it to quantify
receptor B,,,. are open to question.
In contrast to its competition for [‘H]DHA binding, alpren-
olol had a monophasic competition for the binding of the other
/3-adrenergic receptor antagonist, [‘H]CGP-12177, and the
competition curve leveled off between 0.1 and 100 tM. These
data suggest that [‘H]CGP-12177 must be a more selective /3-
adrenergic receptor radioligand. Saturation data for [‘H]CGP-
12177, whether analyzed by Scatchard or LIGAND analysis of
specific binding as defined by alprenolol or by LIGAND analy-
sis of total binding, yielded comparable B,,,. values, reinforcing
this conclusion. Indeed, the , receptor-selective drugs did
not compete for [‘H]CGP-12177 binding at concentrations
lower than 100 nM. Also, the B ,,,,,  calculated by the LIGAND
analysis of total [‘H]DHA binding was close to the B015. calcu-
lated by LIGAND for specific [‘H]CGP-12177 binding. Isopro-
terenol competed in a monophasic way for [‘H]CGP-12177
binding and the presence of GTP in the incubation mixture
significantly shifted the curves to the right, by a factor of 3.
Because in the presence of GTP the [‘H]CGP-12177 binding
sites are homogeneous with respect to agonist affinity, we
interpret these results to suggest that, in our assay system (in
the absence of divalent cations), the /3-adrenergic receptors are
not in a high affinity agonist binding state and GTP has a
significant, although small, effect on the low affinity agonist
binding state of the receptor. However, when 1 mM EDTA was
added during membrane preparation and 2.5 mM Mg2 was
added in the incubation mixture (27), 60% of isoproterenol
competition for [‘H]CGP-12177 is of higher affinity (K, = 35
nM) and is sensitive to GTP (data not shown).
It is of interest that the LIGAND analysis of total binding
of [‘H]CGP-12177 yielded a slightly, but significantly, lower
B,,,5. than the LIGAND analysis of alprenolol-defined specific
[‘H]CGP-12177 binding. This observation suggests that, al-
though [:H]CGp12177 is a far more selective /3-adrenergic
receptor ligand than is [:H]DHA a small component of its
binding may occur to another site. However, this is argued
against by the fact that the alprenolol competition curve can
only be resolved into a single site by LIGAND. Competition
curves of nonradioactive CGP-12177 for [‘H]DHA binding
clarify this observation. CGP-12177 competes for [‘H]DHA
binding with three components. Two components have high
affinity (K, = 0.13 and 9.41 nM). The highest affinity compo-
nent has a K, and Bmax identical to those determined from the
direct binding of [‘H]CGP-12177 in saturation studies. The
second component has a Bma. that is identical to the difference
between the B,,5 of [‘H]CGP-12177 binding and the B,,,,,, for
[‘H]DHA binding, determined from their total binding by
LIGAND. This suggests that [‘H]CGP-12177 labels only a
component (approximately 80%) of the /3-adrenergic receptors
that are labeled by [‘H]DHA. Two possibilities could explain
this observation. 1) Because the subtype selectivities of [:H]
CGP-12177 and [“H]DHA for /3,- and $2-adrenergic receptors
are different, these two sites could represent /3 - and 132-adre-
nergic receptors. However, the relative proportion of /3, to $2
receptors in the cortex is approximately 4 to 1. Furthermore,
[3H]DHA has a selectivity for $2 receptors over /3, receptors of
about 2.3-fold (8). It is known that [‘H]CGP-12177 has a
selectivity for /3, receptors in non-CNS tissue of approximately
2.7-fold (28). Our experiments comparing cortex with cerebel-
lum binding of [‘H]CGP-12177 suggest that its selectivity for
/3, - versus f32-adrenergic receptors is less than a factor of 2 in
the CNS. Thus, the two highest affinity components of CGP-
12177 competition for [‘H]DHA binding, with K, values of 0.13
and 9.41 nM, cannot represent the differential affinities of
CGP-12177 for /3,- and $2-adrenergic receptors. 2) CGP-12177
is known to be very hydrophilic, whereas [‘H]DHA is lipophilic.
This suggests that the lower affinity component of CGP-12 177
competition for [‘H]DHA binding may represent an “apparent”
lower affinity binding site caused by the lower accessibility of
CGP-12177 for receptor sites within the lipid environment of
the membrane that are easily accessible to [‘H]DHA. This 9.41
nM affinity site of CGP-12177 is not the serotonergic site,
because its B,,,,. is much lower than that observed for [H]DHA
binding to the putative serotonergic site and the serotonergic
5HT1R drugs do not compete for any [‘H]CGP-12177 binding
at concentrations less than 100 nM.
In conclusion, [‘H]DHA is not a satisfactory ligand for the
characterization of /3-adrenergic receptors if nonspecific bind-
ing is defined using classical agonists or antagonists. [‘H]DHA
can be used to quantify /3-adrenergic receptors if its total
binding is analyzed by the computer program LIGAND or if
selective /3-adrenergic receptor antagonists are used to define
nonspecific binding. This is not simply a methodological issue,
because we show in the accompanying paper that the failure to
recognize the presence of this non-/3-adrenergic component of
[‘H]DHA binding and its independent regulation has led to the
misinterpretation of data relating to the mechanism of action
of antidepressant drugs and the permissive role that serotoner-
gic systems play in the regulation of (3-adrenergic receptor
number.
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